Cardiol Therapeutics Inc. (CRDL) stock
CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.86−0.02 (-2.28%)
Close on Nov 20, 2026Market cap $86.48MP/E –Yield –
Cardiol Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was C$14.02M, up 0.0% from the year before. The highest annual figure on record is C$18.96M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | C$14.02M | +0.0% |
| FY2024 | Dec 31, 2024 | C$14.01M | -1.5% |
| FY2023 | Dec 31, 2023 | C$14.22M | -25.0% |
| FY2022 | Dec 31, 2022 | C$18.96M | +74.4% |
| FY2021 | Dec 31, 2021 | C$10.87M | +2.5% |
| FY2020 | Dec 31, 2020 | C$10.60M | – |
See a number that looks wrong?